About the Team
We’re a tight-knit team of proven drug hunters, deep learning researchers, and software engineers united by a common mission — drive AI innovation in biochemistry, discovering and developing groundbreaking therapies for patients suffering from severe disorders.
Genesis AI team is focused on developing foundation models for drug discovery by conducting fundamental research at the intersection of machine learning, physics, and computational chemistry, as well as engineering robust software systems that enable running large scale simulations and training generative and predictive AI models designed to learn from all kinds of molecular data, leveraging our cluster with 1000s of GPUs and 10,000s of CPUs.
About the Role
We’re seeking an experienced ML Research Scientist to shape and lead the ML research agenda for generative modeling of molecular systems, which is instrumental to our mission. You will be at the forefront of pioneering research initiatives, driving the continuous evolution and enhancement of our AI platform, while collaborating with exceptional engineers, researchers, and a team of biochemistry experts.
Positions are available at various levels of seniority: Senior, Staff, and Principal.
About Genesis Therapeutics
Genesis Therapeutics is unifying AI and biotech to discover novel and breakthrough treatments for patients with severe and devastating conditions. Genesis was founded on groundbreaking molecular ML research and since has established itself as the industry leader in AI for small molecule drug discovery. Our team of accomplished biotech leaders and expert drug hunters joins forces with deep learning researchers and software engineers who are pioneering predictive and generative AI technologies for molecules.
Our team has created the industry's most advanced molecular AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery and to enable the discovery of novel first-in-class and best-in-class small molecule drugs for challenging and/or undruggable targets.
The company has leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has signed AI-focused platform collaborations with major pharmaceutical companies, including most recently Incyte Corporation (Feb 2025) and Gilead Sciences (Sept 2024).
We raised a $200M series B in August 2023, and have raised over $300M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures.
Genesis is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego. We are proud to be an inclusive workplace and an Equal Opportunity Employer.